GLP-1 Coverage Guide is a private website. We are not Medicare, the Centers for Medicare & Medicaid Services (CMS), or any government agency, and we are not affiliated with or endorsed by them.
Text size:

What is the Medicare GLP-1 Bridge program?

Short answer: a temporary Medicare demonstration that lets eligible people with Medicare drug coverage get certain GLP-1 weight-loss medications — Wegovy, Zepbound (KwikPen), or Foundayo — for a flat $50 per month, from July 1, 2026 through December 31, 2027.

Last verified against CMS: July 21, 2026

Program timeline: launched July 1, 2026; Open Enrollment windows fall 2026 and fall 2027; program ends December 31, 2027.July 1, 2026Program startsYou are hereOpen Enrollment ’26Oct 15 – Dec 7Open Enrollment ’27Last one before the endDec 31, 2027Program ends — no successor announced
Every month you wait is a $50 month you can’t get back — the end date is fixed, your start date isn’t.

How it works

Why it exists — and why it's temporary

Medicare has historically been barred from covering drugs for weight loss alone. CMS designed a broader experiment (the BALANCE Model) to test coverage through Part D plans, but its Medicare component was postponed when too few plans signed up. The Bridge is the stopgap: a direct federal demonstration that skips the plans entirely. It was originally announced as a six-month program and extended through December 2027 — but as of today there is no announced path for coverage after 2027. If you may qualify, waiting has a real cost.

The fine print that surprises people

Check your eligibility →

Sources: CMS — Medicare GLP-1 Bridge · KFF — the BALANCE Model and the GLP-1 Bridge